Abstract
BackgroundUse of immune checkpoint inhibitors in advanced melanoma is challenging in patients with a history of immune therapy related colitis or pre-existing inflammatory bowel disease (Crohn’s disease or ulcerative colitis).1...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
